Q Chip proves to be (Bio)compatible
Q Chip, the pioneering microfluidic venture, has signed a collaborative research deal with Biocompatibles International, a medical device company focused on the treatment of cardiovascular disease, cancer and benign tumours.
Q Chip, the pioneering microfluidic venture, has signed a collaborative research deal with Biocompatibles International, a medical device company focused on the treatment of cardiovascular disease, cancer and benign tumours.
The aim of the collaboration is to develop a novel microfluidic device for the production of Biocompatibles' next generation microspheres.
Under the terms of the agreement Q Chip will receive a combination of fees and milestone payments and Biocompatibles will have exclusive rights to Q Chip's intellectual property portfolio for certain applications for the duration of the project.
Q Chip's microfluidic engineering technology enables the development and production of monodisperse, uniformly shaped microparticles. Q Chip achieves this by the precision formation of particles in micron-scale capillaries etched in bioinert wafers, operated in large parallel arrays to enable high throughput. The processing system is designed to improve manufacturing efficiency and reduced wastage.